Separator

Iraq's Pharmaceutical Industry Challenges & Opportunities

Separator
Iraq's Pharmaceutical Industry Challenges & Opportunities

Rachita Sharma, Managing Editor, 0

The Iraqi pharmaceutical industry, valued at over $3 billion in 2024, is rapidly growing but remains heavily dependent on imports for over 90% of its medicine needs.

While state-owned firms like Samara Drugs Industry (SDI) and private players such as Pioneer Pharma exist, the market is shifting toward localized production and investment.

There is a strong, untapped market for investment due to low domestic production capacity. However, challenges include the need for modernization, navigating complex regulations, and competition from imported brands.

Navigating the Iraqi pharma sector requires industry expertise and the conviction to build something impactful. The current edition of CEOInsights Asia highlights few pharma leaders from Iraq who are redefining the industry’s growth.

One of the featured leaders is Fatima Shubber, Managing Director of Shubber Scientific Bureau, is a pharmacist and industry leader who has transformed the company into a trusted representative for global pharmaceutical brands. Since 2010, she has driven partnerships, innovation, and patient centered initiatives, shaping Iraq’s healthcare landscape while promoting quality, access, and ethical leadership.

Talking about Iraq’s pharma industry, Fatima says, “The pharmaceutical sector in Iraq is evolving rapidly, and challenges will always exist. Approach them with determination and a growth mindset. When you do, every obstacle becomes an opportunity to innovate, grow, and elevate the level of service you provide to your community.”

To read more such insights and advice, read the current edition of CEOInsights Asia magazine.

Let us know your thoughts.

Current Issue




🍪 Do you like Cookies?

We use cookies to ensure you get the best experience on our website. Read more...